BioHarvest Sciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

BioHarvest Sciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-4.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-4.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Revenues Tell The Story For BioHarvest Sciences Inc. (CSE:BHSC) As Its Stock Soars 26%

Nov 17

BioHarvest Sciences Inc.'s (CSE:BHSC) P/S Is On The Mark

Mar 17

Investors Interested In BioHarvest Sciences Inc.'s (CSE:BHSC) Revenues

Dec 01

Don't Ignore The Fact That This Insider Just Sold Some Shares In BioHarvest Sciences Inc. (CSE:BHSC)

Jan 17

How Much Of BioHarvest Sciences Inc. (CSE:BHSC) Do Insiders Own?

Jan 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BHSC şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BHSC şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

BioHarvest Sciences Piyasaya Karşı Temettü Getirisi

BHSC temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BHSC)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Personal Products)	2.9%
Analist tahmini (BHSC) (3 yıla kadar)	n/a

Önemli Temettü: BHSC şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BHSC şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BHSC şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BHSC herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

BioHarvest Sciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Revenues Tell The Story For BioHarvest Sciences Inc. (CSE:BHSC) As Its Stock Soars 26%

BioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)

New major risk - Financial position

New minor risk - Market cap size

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)

Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc.'s (CSE:BHSC) P/S Is On The Mark

BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024

BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding

Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products

Investors Interested In BioHarvest Sciences Inc.'s (CSE:BHSC) Revenues

Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding

Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)

BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)

BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)

Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)

No independent directors

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding

BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022

BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)

Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure

BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding

BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement

First quarter 2021 earnings released

Full year 2020 earnings released

Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical

Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report

New 90-day high: CA$0.57

BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media

BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding

BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding

New 90-day high: CA$0.43

Don't Ignore The Fact That This Insider Just Sold Some Shares In BioHarvest Sciences Inc. (CSE:BHSC)

BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board

How Much Of BioHarvest Sciences Inc. (CSE:BHSC) Do Insiders Own?

New 90-day high: CA$0.21

Third quarter 2020 earnings released: US$0.004 loss per share

BioHarvest Sciences Inc. Announces the Appointment of Rhona Applebaum as Its Senior Consultant for Regulatory and Environmental Affairs

BioHarvest Sciences Inc. Appoints Roberto Chait to Advisory Board

BioHarvest Sciences Inc. announced that it has received CAD 3.807759 million in funding

BioHarvest Sciences Inc. Signs Exclusive Sales and Distribution Agreement with Batory Foods

BioHarvest Sciences Inc. announced that it expects to receive CAD 3.814208 million in funding

First half earnings released

BioHarvest Sciences Inc. announced that it has received CAD 0.652379 million in funding

BioHarvest Ltd. completed the acquisition of Canna-V-Cell Sciences Inc. (CNSX:CNVC) in a reverse merger transaction.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin